CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4-antibodies (CTLA-4) and programmed cell death (PD) 1/PD ligand 1 (PD-L1), have revolutionized immune-management of advanced NSCLC [10].